Trial Enrollment Begins for Abbott’s Hep C Trio
Abbott Announces Phase 3 Hepatitis C Program Details
– Interferon-free Hepatitis C Regimens will be Studied in Broad Patient Populations across Multiple Countries
ABBOTT PARK, Illinois, Nov. 13, 2012 /PRNewswire/ — Abbott today released details on its phase 3 hepatitis C registrational program following promising results from its phase 2b clinical trial, known as Aviator, presented at the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) in Boston. The phase 3 clinical trials are designed to evaluate safety and efficacy of a 12-week regimen of three direct acting antivirals (DAA), with and without ribavirin, for the treatment of HCV in genotype 1 (GT1) non-cirrhotic, treatment-naïve and treatment-experienced patients. An additional phase 3 trial will study triple-DAAs, with ribavirin, in patients with cirrhosis for 12 or 24 weeks.
The phase 3 program, which is currently open for enrollment, will include more than 2,000 patients with HCV genotype 1, with trial sites in 29 countries. The DAAs in the studies include ABT-450/r (protease inhibitor and ritonavir), ABT-267 (NS5A inhibitor) and ABT-333 (non-nucleoside polymerase inhibitor). Treatment duration will be 12 weeks in non-cirrhotic patients, and 12 or 24 weeks in cirrhotic patients. All patients will be followed for 48 weeks post-treatment. Co-formulated tablets of ABT-450/r and ABT-267 will be used in the phase 3 trials.
More information on the trials is available at www.clinicaltrials.gov [http://www.clinicaltrials.gov/].
Physicians and patients interested in participating in Abbott’s HCV Clinical Trials should visit www.discoverhepc.com/.
Continue reading this entire article:
BIT225 in Phase II Trial for HIV and Hep C Co-Infection
Food Coma's Impact on Those Battling Hepatitis C